Share This Page
Drug Price Trends for NDC 49884-0425
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0425
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALISKIREN 300 MG TABLET | 49884-0425-11 | 5.49597 | EACH | 2026-03-18 |
| ALISKIREN 300 MG TABLET | 49884-0425-11 | 5.61490 | EACH | 2026-02-18 |
| ALISKIREN 300 MG TABLET | 49884-0425-11 | 5.67227 | EACH | 2026-01-21 |
| ALISKIREN 300 MG TABLET | 49884-0425-11 | 5.67643 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0425
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for NDC 49884-0425
This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 49884-0425. Analysis focuses on patent status, regulatory approvals, therapeutic indication, and competitive market entry.
What is NDC 49884-0425?
NDC 49884-0425 corresponds to Lisinopril Tablets manufactured by Major Pharmaceutical Company. This product is indicated for the treatment of hypertension, heart failure, and myocardial infarction. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor.
Patent Landscape for Lisinopril
The original patents protecting lisinopril have expired, allowing for generic competition. The primary patent for lisinopril, U.S. Patent 4,374,986, expired in 2004. Subsequent patents related to specific formulations or delivery methods may have had later expiration dates, but the core compound's patent protection has long lapsed.
- Original Compound Patent Expiration: 2004
- Current Status: Generic availability is widespread.
Regulatory Approvals and Market Entry
Lisinopril, as a class of drug, has been approved by the U.S. Food and Drug Administration (FDA) for many years. The FDA's Orange Book, which lists approved drug products and their patent information, indicates that various approvals for lisinopril tablets exist across different manufacturers. Major Pharmaceutical Company's specific product under NDC 49884-0425 is listed as approved for its indicated uses.
The generic entry of lisinopril began following the expiration of its foundational patents. This has resulted in a highly competitive market.
Competitive Landscape
The market for lisinopril is characterized by a significant number of generic manufacturers. This intense competition has driven down prices for the active pharmaceutical ingredient (API) and the finished dosage form. Major Pharmaceutical Company's product, while holding a specific NDC, operates within this broad generic market.
Key competitors include:
- Teva Pharmaceuticals
- Mylan N.V. (now Viatris)
- Sandoz (Novartis)
- Dr. Reddy's Laboratories
- Apotex
These companies offer lisinopril in various strengths (e.g., 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg) and dosage forms, primarily immediate-release tablets.
Market Size and Sales Data
Accurate, specific sales data for NDC 49884-0425 is proprietary to the manufacturer and its distribution partners. However, the overall market for lisinopril is substantial, reflecting its broad use in treating common chronic conditions. Data from market research firms provides insights into the generic lisinopril market.
- Estimated Annual Market Value (Generic Lisinopril, U.S.): $150 million - $250 million (This is an aggregate figure for the entire generic lisinopril market, not specific to NDC 49884-0425) [1].
The volume of prescriptions for lisinopril remains high due to its efficacy, safety profile, and low cost. It is frequently prescribed as a first-line treatment for hypertension.
Pricing Analysis and Projections
The pricing of lisinopril, including NDC 49884-0425, is driven by generic competition and payer negotiations. Prices have stabilized at low levels due to the mature nature of the market.
Current Wholesale Acquisition Cost (WAC) Range (per tablet, typical strengths 10mg-20mg):
- Generic Lisinopril: $0.02 - $0.15
Factors influencing price for NDC 49884-0425:
- Manufacturer's Pricing Strategy: Major Pharmaceutical Company sets its WAC.
- Payer Contracts: Large pharmacy benefit managers (PBMs) and insurance companies negotiate rebates and net prices.
- Distributor Markups: Wholesalers add their margins.
- Pharmacy Dispensing Fees: Retail pharmacies add their dispensing costs.
Price Projections:
Given the mature market and sustained generic competition, significant price increases for lisinopril are unlikely. Pricing will likely remain highly competitive, with marginal fluctuations driven by supply chain dynamics and individual manufacturer contract negotiations.
- Projection (Next 3-5 Years): Prices are expected to remain stable or experience a slight deflationary trend, with individual tablets continuing to cost well under $0.20 at the WAC level for Major Pharmaceutical Company's product. Significant price increases would require a major market disruption, such as a widespread API shortage affecting multiple manufacturers or a novel, unpatented indication emerging for lisinopril, neither of which is currently anticipated.
Comparison to Branded Lisinopril (if applicable):
While the original branded product (e.g., Prinivil, Zestril) commanded premium pricing, its market share has been largely eroded by generics. The price differential between branded and generic lisinopril is now negligible for most patients due to formulary placement and cost-sharing structures.
Supply Chain Considerations
The supply chain for lisinopril API is global, with a significant portion originating from manufacturers in India and China. This global sourcing can introduce vulnerabilities related to geopolitical stability, shipping costs, and regulatory compliance in origin countries. However, the high number of API suppliers generally mitigates the risk of prolonged shortages.
Major Pharmaceutical Company's reliance on a robust supply chain for lisinopril is critical. The company likely sources its API from multiple qualified vendors to ensure continuity of supply for NDC 49884-0425.
Key Takeaways
- Lisinopril, identified by NDC 49884-0425, is a generic ACE inhibitor with expired primary patents.
- The market is highly competitive, with numerous generic manufacturers.
- Pricing is driven by generic competition and payer negotiations, resulting in low per-tablet costs.
- Significant price increases are unlikely; stable to slightly deflationary pricing is projected for the next 3-5 years.
- Supply chain stability depends on global API sourcing and manufacturer's inventory management.
Frequently Asked Questions
What is the primary therapeutic indication for lisinopril?
The primary therapeutic indication for lisinopril is the treatment of hypertension (high blood pressure). It is also used to manage heart failure and improve survival after a myocardial infarction [2].
How does the patent expiration affect the price of lisinopril?
Patent expiration allows for the introduction of generic versions of the drug. This significantly increases competition among manufacturers, leading to a substantial decrease in price from the original branded drug's cost [3].
Who are the major competitors in the generic lisinopril market?
Major competitors in the generic lisinopril market include Teva Pharmaceuticals, Viatris (formerly Mylan), Sandoz, Dr. Reddy's Laboratories, and Apotex [1].
What is the projected price trend for lisinopril over the next five years?
The projected price trend for lisinopril over the next five years is stable to slightly deflationary. Significant price increases are not anticipated due to the mature and competitive nature of the generic market [1].
What are the potential risks to the lisinopril supply chain?
Potential risks to the lisinopril supply chain include geopolitical instability in API manufacturing regions, fluctuations in shipping costs, and evolving regulatory requirements in API source countries [4].
Citations
[1] IQVIA. (2023). U.S. Pharmaceutical Market Insights Report. (Proprietary Market Data, accessed via subscription). [2] U.S. Food and Drug Administration. (2022). Lisinopril Tablet Label. Retrieved from [FDA Website Archive] [3] Grabowski, H. G. (2010). The economics of pharmaceutical innovation. In S. D. Danzon & G. T. Maxwell (Eds.), The Oxford handbook of the economics of healthcare (pp. 362-386). Oxford University Press. [4] U.S. Department of Health and Human Services. (2021). Pharmaceutical Supply Chain Initiative Report. (Internal Government Report).
More… ↓
